Developing a single-dose, intranasal, live-attenuated vaccine against COVID-19
Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.
There are currently no licensed vaccines against COVID-19, and the pandemic continues to spread in the U.S. and around the world. CodaVax-COVID is a single-dose, intranasal, live-attenuated vaccine against COVID-19, generated using Codagenix’s proprietary deoptimization technology.
Target customized oncolytics to treat primary tumors and shrink off-site metastases
177,000
RSV hospitalizations among adults 65+ no vaccine
48.8 million
Flu cases in 2017-18, current vaccines <37% effective
1 in 8
US women (about 12%) will develop invasive breast cancer during lifetime.
Our breakthrough approach to live-attenuated virus design
1. Recode
2. Synthesize
3. Transfect
4. Recover
-
September 22, 2020
Serum Institute of India Initiates Manufacturing of Codagenix’s Intranasal Live-Attenuated COVID-19 Vaccine Candidate
-
September 16, 2020
Synthetic biologists have created a slow-growing version of the coronavirus to give as a vaccine